Emerging Markets

August 2013

Colorectal Cancer in Turkey

Report Authors
Natalia Reoutova, M.A., M.Sc.
Prachi Vora, M.P.H.

Introduction:

The Turkish CRC market will grow at 4% annually between 2012-2017 and the number of CRC incident cases will almost double between 2012-2022. Growing CRC population, entry of several promising new agents and persistent use of branded agents are the key factors driving this market. In this report, we examine the trends within Turkey’s CRC pharmaceutical market, which is characterized by the wide use of KRAS testing, universal healthcare, high patient shares for targeted therapies, the anticipated launch of several emerging therapies, and Turkish government’s stringent price controls.

Questions Answered in This Report:

  *   Between 2012-2017, five new therapies are expected to enter Turkey’s CRC market. Will these agents be entering existing drug classes or will they feature novel mechanisms of action? How widely will these agents be used in Turkey and will they pose considerable competition to the current therapies? What are Turkish oncologists’ perceptions of the emerging therapies?

  *   Pricing of therapies and reimbursement policies in the public sector are major factors influencing expenditure on CRC treatments in Turkey. How does the pricing of branded and generic agents used in treatment of CRC vary between Turkey and the major markets? Which groups of Turkish patients are eligible for government-reimbursed treatment of CRC? Which targeted therapies are currently available to the Turkish patients and is it likely that the patient shares of those agents will change substantially in the next several years?

  *   The Turkish CRC market will grow at 4% annually between 2012-2017. What was the size of the Turkish CRC market in 2012? How large will the market be in 2017? What factors will drive growth in this market? What factors will constrain it?

  *   The number of incident cases of CRC in Turkey will nearly double between 2012 and 2022. What was the number of incident cases of CRC in Turkey in 2012? What was the stage distribution of diagnosed cases in 2012 and will it change by 2022? How many patients were diagnosed with colon cancer and how many patients were diagnosed with rectal cancer?

Scope:

Primary research: 73 oncologists surveyed across Turkey. Separate in-depth interviews with 8 Turkish oncologists.

Epidemiology: Total incident cases of CRC in Turkey over a ten-year period (2012-2022) by age, stage, gender, and localization.

Current therapies and medical practice: Reporting use of brands and generics for the CRC treatments available in Turkey.

Pricing and reimbursement: Prices of CRC therapies in Turkey versus other major markets and analysis of the impact of government reimbursement on treatment trends.

Market forecast features: Our analysis evaluates rates of CRC progression and rates of drug treatment with CRC therapies, across all stages of the disease. We include a detailed forecast of current and emerging therapies within platinum agents, antimetabolites, topoisomerase inhibitors, angiogenesis inhibitors, and EGFR inhibitors from 2012 through 2017, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - Alchemia
  • - Atafarm
  • - Bayer
  • - Biothera
  • - Eli Lilly
  • - Light Sciences Oncology
  • - Merck
  • - Novartis
  • - Orna
  • - Pfizer
  • - Roche
  • - Sanofi
  • - Taiho
  • - Vaccinogen
Decision Resources Group brands include: